

STERILOX[®]

13 April 2005

Initial Microbiological Study Findings - Sterilox Fog Effective Against MRSA and Acinetobacter.

Sterilox Technologies International, the UK's leading non-toxic biocide and bacteria free rinse water specialist, has completed a four week 'fogging' study with one of London's leading teaching hospitals, into the efficacy of Sterilox disinfectant against Methicillin-Resistant Staphylococcus Aureus (MRSA), and Acinetobacter species. Initial findings indicate that Sterilox biocide is effective against MRSA and Acinetobacter, micro-organisms that can be responsible for Hospital Acquired Infections (HAI).

The results will be featured in a joint research paper submitted to a world leading peer reviewed medical journal.

Fogging involves converting Sterilox into a fine mist, which is used to 'fog' wards and other hospital environments. The fog can be used to control levels of MRSA, Acinetobacter and other bacteria that have developed a resistance to conventional antibiotics. The additional advantage of Sterilox is that because it is non-toxic, wards can be returned to full operation in a shorter time period than normally associated with fogging with toxic chemicals.

Sterilox will formally announce its MRSA and environmental bio-decontamination application within the next six to nine months. It is anticipated that its fogging process will complement and augment existing infection control practices and initiatives.

HAI costs the NHS approximately £1bn per annum, affects over 100,000 patients and causes approximately 5,000 deaths a year in Britain. MRSA, the most common HAI in the UK, was first recorded in the 1960s. Apart from Greece, Britain has the highest recorded incidence of MRSA in Europe.

Commenting for Sterilox Technologies International, Paul Donnelly, Manager Director said, "Our initial findings indicate that Sterilox can be a highly effective weapon in the war against HAI in general and MRSA in particular.

“ The truth is, Infection Control Directors have to deploy a multi-tiered strategy if they want to begin to manage Britain’s HAI and MRSA problem more effectively. Reducing patient-to-patient contamination with improved handwashing and decontaminating the environment with a non-toxic efficacious biocide such as ours, will be a highly potent and effective combination.”

- ENDS -

Notes to editors

Sterilox Technologies Inc., is a privately-owned corporation, established in 1996 and based in Delaware, US. The company’s European headquarters are in Stafford. U.K.

The company’s core product is Sterilox, a safe, fast-acting, broad-spectrum biocide, often referred to as ‘super-oxidized’ water. Sterilox is produced when required using a patented electrolytic cell from water and common salt (sodium chloride), and the main active component of the mixture is hypochlorous acid, a powerful disinfectant. Solutions are fast acting, non-toxic and non-hazardous making them ideal for the rapid, cold sterilisation of heat-sensitive surgical instruments such as endoscopes.

The company supplies a complete range of generators and automated washer/disinfectors plus Optident Sterilox, a system developed specifically for the dental market.

Further information

For further press information please refer to www.sterilox.co.uk or call:

Penny Jones/Howard de Souza
Direct Telephone: 01763 848 777
Email: penny@thesevenpartnership.com